Carolina Soares

Carolina Soares

Auto-generated profile, based on publicly available information

Carolina Soares

Department of Psychiatry, School of Medicine, University of Pittsburgh, PA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2024 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
CSCarolina Soares
Carolina Soares
LRLucas Uglione Da Ros
Lucas Uglione Da Ros
LMLuiza Santos Machado
Luiza Santos Machado
ARAndreia Rocha
Andreia Rocha
GLGabriela Lazzarotto
Gabriela Lazzarotto
EZEduardo Zimmer
Eduardo Zimmer

25 September 2023 in Nature Aging
Verified
Journal Article
Closed access
PDF file
JFJoão Pedro Ferrari-Souza
João Pedro Ferrari-Souza
BBBruna Bellaver
Bruna Bellaver
PFPâmela C. L. Ferreira
Pâmela C. L. Ferreira
ABAndréa L. Benedet
Andréa L. Benedet
GPGuilherme Povala
Guilherme Povala
TPTharick A. Pascoal
Tharick A. Pascoal

1 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
FRFrancieli Rohden
Francieli Rohden
PFPamela C. L. Ferreira
Pamela C. L. Ferreira
BBBruna Bellaver
Bruna Bellaver
JFJoão Pedro Ferrari-Souza
João Pedro Ferrari-Souza
CACristiano S. Aguzzoli
Cristiano S. Aguzzoli
TPTharick A. Pascoal
Tharick A. Pascoal
Previous studies suggest glial and neuronal changes may trigger synaptic dysfunction in Alzheimer’s disease (AD), but the link between their markers and synaptic abnormalities in the living brain remains unclear. We investigated the association between glial reactivity and synaptic dysfunction biomarkers in cerebrospinal fluid (CSF) from 478 individuals in cognitively unimpaired (CU) and cognitively impaired (CI) individuals. We measured amyloid-β (Aβ), phosphorylated tau (pTau181), astrocyte reactivity (GFAP), microglial activation (sTREM2), and synaptic markers (GAP43, neurogranin). CSF GFAP levels were associated with presynaptic and postsynaptic dysfunction, independent of cognitive status or Aβ presence. CSF sTREM2 levels were related to presynaptic markers in cognitively unimpaired and impaired Aβ+ individuals, and to postsynaptic markers in cognitively impaired Aβ+ individuals. Notably, CSF pTau mediated the relationships between GFAP or sTREM2 and synaptic dysfunction. Our findings, validated in two independent cohorts (TRIAD and ADNI), reveal a distinct pattern of glial contribution to synaptic degeneration.

1 July 2021 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
VSVirginia L. De Sousa
Virginia L. De Sousa
SASuzana B. Araújo
Suzana B. Araújo
LALeticia M. Antonio
Leticia M. Antonio
MSMariana Silva-Queiroz
Mariana Silva-Queiroz
LCLilian C. Colodeti
Lilian C. Colodeti
CFClaudia pinto Figueiredo
Claudia pinto Figueiredo

Verified
Journal Article
Open access
PDF file
DPDanilo Predes
Danilo Predes
LMLorena A. Maia
Lorena A. Maia
IMIsadora Matias
Isadora Matias
HAHannah Paola Mota Araujo
Hannah Paola Mota Araujo
CSCarolina Soares
Carolina Soares
JAJose Abreu
Jose Abreu
The Wnt/β-catenin signaling pathway dictates cell proliferation and differentiation during embryonic development and tissue homeostasis. Its deregulation is associated with many pathological conditions, including neurodegenerative disease, frequently downregulated. The lack of efficient treatment for these diseases, including Alzheimer’s disease (AD), makes Wnt signaling an attractive target for therapies. Interestingly, novel Wnt signaling activating compounds are less frequently described than inhibitors, turning the quest for novel positive modulators even more appealing. In that sense, natural compounds are an outstanding source of potential drug leads. Here, we combine different experimental models, cell-based approaches, neuronal culture assays, and rodent behavior tests with Xenopus laevis phenotypic analysis to characterize quercitrin, a natural compound, as a novel Wnt signaling potentiator. We find that quercitrin potentiates the signaling in a concentration-dependent manner and increases the occurrence of the Xenopus secondary axis phenotype mediated by Xwnt8 injection. Using a GSK3 biosensor, we describe that quercitrin impairs GSK3 activity and increases phosphorylated GSK3β S9 levels. Treatment with XAV939, an inhibitor downstream of GSK3, impairs the quercitrin-mediated effect. Next, we show that quercitrin potentiates the Wnt3a-synaptogenic effect in hippocampal neurons in culture, which is blocked by XAV939. Quercitrin treatment also rescues the hippocampal synapse loss induced by intracerebroventricular injection of amyloid-β oligomers (AβO) in mice. Finally, quercitrin rescues AβO-mediated memory impairment, which is prevented by XAV939. Thus, our study uncovers a novel function for quercitrin as a Wnt/β-catenin signaling potentiator, describes its mechanism of action, and opens new avenues for AD treatments.

13 January 2026 in Neurology
Verified
Journal Article
Open access
PFPamela C.L. Ferreira
Pamela C.L. Ferreira
BBBruna Bellaver
Bruna Bellaver
GPGuilherme Povala
Guilherme Povala
GBGuilherme Bauer-Negrini
Guilherme Bauer-Negrini
CACristiano Schaffer Aguzzoli
Cristiano Schaffer Aguzzoli
TPTharick A. Pascoal
Tharick A. Pascoal
Plasma phosphorylated tau 217 (p-tau217) levels have been shown to parallel neurofibrillary tangle and cognitive decline over time. Although recent clinical trials have demonstrated exploratory drug effects on plasma p-tau217, little is known about plasma p-tau217 effect size and performance as an endpoint in Alzheimer disease (AD) clinical trials. Therefore, the objective of this study was to assess the longitudinal performance and potential utility of plasma p-tau217 as a primary endpoint in early-stage AD clinical trials. This retrospective study included participants from 4 cohorts: ADNI (a multisite observational study), BICWALZS (a South Korean memory clinic-based cohort), MYHAT-NI (a Southwestern Pennsylvania population-based cohort), and WRAP (older adults at risk for AD). Eligible participants had plasma p-tau217 measurements at least at 2 timepoints, along with baseline Aβ PET imaging and clinical assessments. Linear mixed-effects models were used to assess associations between plasma p-tau217 trajectories and clinical or biomarker outcomes. Effect size was defined as the mean annual rate of change in p-tau217 divided by its standard deviation. We calculated the sample size required for a hypothetical clinical trial designed to detect a 25% drug effect with 80% power at a 0.05 test level. A total of 716 individuals were included in the analysis: 413 cognitively unimpaired (CU) participants (58.6% female; mean age = 70.6 years, SD = 7.9) and 303 cognitively impaired (CI) participants (54.7% female; mean age = 73.2 years, SD = 7.4). In Aβ-positive individuals, the annual rate of change in plasma p-tau217 was similar between CU (0.07 pg/mL/y, SD = 0.11) and CI (0.08 pg/mL/y, SD = 0.13) groups. Effect size was 0.64 and 0.62 in CU and CI Aβ-positive individuals, respectively. The minimum sample size required per study group to detect a 25% drug effect was 610 for the CU Aβ-positive and 664 for the CI Aβ-positive group. Notably, selecting individuals with intermediate Aβ levels (Centiloid 20-40) yielded higher effect sizes (CU: 0.85; CI: 0.72), which reduced the required sample sizes per study group to 342 for CU and 492 for CI. Our findings support that changes in plasma p-tau217 represent a robust endpoint for clinical trials targeting CU or CI individuals with Aβ pathology.